molecular pharmacology

ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies
Oronza A. Botrugno, Silvia Bianchessi, Desirée Zambroni, Michela Frenquelli, Daniela Belloni, Lucia Bongiovanni, Stefania Girlanda, Simona Di Terlizzi, Marina Ferrarini, Elisabetta Ferrero, Maurilio Ponzoni, Magda Marcatti, Giovanni Tonon

Haematologica Nov 2019, haematol.2018.215210; DOI: 10.3324/haematol.2018.215210
The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs
Debora Soncini, Stefania Orecchioni, Samantha Ruberti, Paola Minetto, Claudia Martinuzzi, Luca Agnelli, Katia Todoerti, Antonia Cagnetta, Maurizio Miglino, Marino Clavio, Paola Contini, Riccardo Varaldo, Micaela Bergamaschi, Fabio Guolo, Mario Passalacqua, Alessio Nencioni, Fiammetta Monacelli, Marco Gobbi, Antonino Neri, Giovanni Abbadessa, Sudharshan Eathiraj, Brian Schwartz, Francesco Bertolini, Roberto M. Lemoli, Michele Cea

Haematologica Nov 2019, haematol.2019.224956; DOI: 10.3324/haematol.2019.224956
EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase
Yusuke Saito, Daisuke Sawa, Mariko Kinoshita, Ai Yamada, Sachiyo Kamimura, Akira Suekane, Honami Ogoh, Hidemasa Matsuo, Souichi Adachi, Takashi Taga, Daisuke Tomizawa, Motomi Osato, Tomoyoshi Soga, Kazuhiro Morishita, Hiroshi Moritake

Haematologica Oct 2019, haematol.2019.225953; DOI: 10.3324/haematol.2019.225953
Functional assessment of glucocerebrosidase modulator efficacy in primary patient-derived macrophages is essential for drug development and patient stratification.
Natalie J. Welsh, Christina A. Gewinner, Kavita Mistry, Mumta Koglin, Juniebel Cooke, Matthew Butler, Ben Powney, Malcolm Roberts, James M. Staddon, Anthony H.V. Schapira

Haematologica Sep 2019, haematol.2019.224717; DOI: 10.3324/haematol.2019.224717
Synergistic effects of PRIMA-1Met (APR-246) and Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
Nabih Maslah, Norman Salomao, Louis Drevon, Emmanuelle Verger, Nicolas Partouche, Pierre Ly, Philippe Aubin, Nadia Naoui, Marie-Helene Schlageter, Cecile Bally, Elsa Miekoutima, Rami Rahmé, Jacqueline Lehmann-Che, Lionel Ades, Pierre Fenaux, Bruno Cassinat, Stephane Giraudier

Haematologica Sep 2019, haematol.2019.218453; DOI: 10.3324/haematol.2019.218453
Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells
Koji Takaishi, Masahiro Takeuchi, Shokichi Tsukamoto, Naoya Takayama, Motohiko Oshima, Kenji Kimura, Yusuke Isshiki, Kensuke Kayamori, Yutaro Hino, Nagisa Oshima-Hasegawa, Shio Mitsukawa, Yusuke Takeda, Naoya Mimura, Chikako Ohwada, Tohru Iseki, Sou Nakamura, Koji Eto, Atsushi Iwama, Koutaro Yokote, Chiaki Nakaseko, Emiko Sakaida

Haematologica Sep 2019, haematol.2018.214841; DOI: 10.3324/haematol.2018.214841
Multi-parametric single cell evaluation defines distinct drug responses in healthy hematological cells that are retained in corresponding malignant cell types
Muntasir M. Majumder, Aino-Maija Leppä, Monica Hellesøy, Paul Dowling, Alina Malyutina, Reidun Kopperud, Despina Bazou, Emma Andersson, Alun Parsons, Jing Tang, Olli Kallioniemi, Satu Mustjoki, Peter O'Gorman, Krister Wennerberg, Kimmo Porkka, Bjørn T. Gjertsen, Caroline A. Heckman

Haematologica Aug 2019, haematol.2019.217414; DOI: 10.3324/haematol.2019.217414
EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma
Shao Xie, Fan Wei, Yi-ming Sun, Ying-lei Gao, Lu-lu Pan, Min-jia Tan, Shu-dong Wang, Jian Ding, Yi Chen

Haematologica Jul 2019, haematol.2019.222935; DOI: 10.3324/haematol.2019.222935
Variable readthrough responsiveness of nonsense mutations in hemophilia A
Lluis Martorell, Vicente Cortina, Rafael Parra, Jordi Barquinero, Francisco Vidal

Haematologica Jun 2019, haematol.2018.212118; DOI: 10.3324/haematol.2018.212118
A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease
James G. McArthur, Niels Svenstrup, Chunsheng Chen, Aurelie Fricot, Caroline Carvalho, Julia Nguyen, Phong Nguyen, Anna Prachikova, Fuad Abdulla, Gregory M. Vercellotti, Olivier Hermine, Dave Edwards, Jean-Antoine Ribeil, John D. Belcher, Thiago T. Maciel

Haematologica May 2019, haematol.2018.213462; DOI: 10.3324/haematol.2018.213462

molecular pharmacology

Pages